MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia

European Journal of Haematology

Volumn 85, Issue 3, 2010, Pages 251-256

  Willander, Kerstin ^a,b   Ungerbäck, Jonas ^a   Karlsson, Karin ^c   Fredrikson, Mats ^a   Söderkvist, Peter ^a   Linderholm, Mats ^b  

^a LINKÖPING UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

chronic lymphocytic leukemia; MDM2 SNP309; prognostic markers; TP53 mutations

Indexed keywords

CD19 ANTIGEN; CD23 ANTIGEN; CD5 ANTIGEN; PROTEIN MDM2; PROTEIN P53; IMMUNOGLOBULIN HEAVY CHAIN;

ADULT; AGED; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; DEATH; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; IMMUNOGLOBULIN VARIABLE REGION; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RISK; SINGLE NUCLEOTIDE POLYMORPHISM; GENETICS; GENOTYPE; KAPLAN MEIER METHOD; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; MUTATION; PROMOTER REGION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENOTYPE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; KAPLAN-MEIERS ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53; KAPLAN-MEIER ESTIMATE;

EID: 77955824152     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01470.x     Document Type: Article

References (26)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005 352 : 805 15.
2. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000 408 : 307 10.
3. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M, Lichter P. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000 343 : 1910 6.
4. Zenz T, Kröber A, Scherer K, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 2008 112 : 3322 9.
5. Döhner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J, Stilgenbauer S. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 1995 85 : 1580 9.
6. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P, Fenaux P. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994 84 : 3148 57.
7. Rossi D, Cerri M, Deambrogi C, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009 15 : 995 1004.
8. Michael D, Oren M. The p53-Mdm2 module and the ubiquitin system. Semin Cancer Biol 2003 13 : 49 58.
9. Watanabe T, Hotta T, Ichikawa A, Kinoshita T, Nagai H, Uchida T, Murate T, Saito H. The MDM2 oncogene overexpression in chronic lymphocytic leukemia and low-grade lymphoma of B-cell origin. Blood 1994 84 : 3158 65.
10. Bond GL, Hu W, Bond EE, Robins H, et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004 119 : 591 602.
11. Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002 100 : 1177 84.
12. Bond GL, Levine AJ. A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence in humans. Oncogene 2007 26 : 1317 23.
13. Gryshchenko I, Hofbauer S, Stoecher M, Daniel PT, Steurer M, Gaiger A, Eigenberger K, Greil R, Tinhofer I. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia. J Clin Oncol 2008 26 : 2252 7.
14. Zenz T, Häbe S, Benner A, Kienle D, Döhner H, Stilgenbauer S. The MDM2-309 TG promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemia. Haematologica 2008 93 : 1111 3.
15. Kaderi MA, Mansouri M, Zainuddin N, et al. Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia. Leuk Res 2010 34 : 335 9.
16. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989 5 : 874 9.
17. Van Dongen JJM, Lagerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003 17 : 2257 317.
18. Lind H, Zienolddiny S, Ekstrom PO, Skaug V, Haugen A. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer. Int J Cancer 2006 119 : 718 21.
19. Boersma BJ, Howe TM, Goodman JE, Yfantis HG, Lee DH, Chanock SJ, Ambs S. Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 2006 98 : 911 9.
20. Ohmiya N, Taguchi A, Mabuchi N, Itoh A, Hirooka Y, Niwa Y, Goto H. Mdm2 Promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol 2006 24 : 4434 40.
21. Hirata H, Hinoda Y, Kikuno N, Kawamoto K, Suehiro Y, Tanaka Y, Dahiya R. Mdm2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma. Clin Cancer Res 2007 13 : 4123 9.
22. Ruijs MWG, Schmidt MK, Nevanlinna H, Tommiska J, Aittomäki K, Pruntel R, Verhoef S, van't Veer LJ. The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. Eur J Hum Genet 2007 15 : 110 4.
23. Menin C, Scaini MC, De Salvo GL, et al. Association between MDM2-SNP309 and age at colorectal cancer diagnosis according to p53 mutation status. J Natl Cancer Inst 2006 98 : 285 8.
24. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the national cancer institute working group 1996 guidelines. Blood 2008 111 : 5446 56.
25. Coll-Mulet L, Iglesias-Serret D, Santidrián AF, et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 2006 107 : 4109 14.
26. Seyfried I, Hofbauer S, Stoecher M, Greil R, Tinhofer I. SNP309 as predictor for sensitivity of CLL cells to the MDM2 inhibitor nutlin-3a. Blood 2008 112 : 2168.